Clinical Trials Logo

Clinical Trial Summary

The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04126317
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date November 4, 2019
Completion date November 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT06184360 - Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Completed NCT04847895 - Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
Active, not recruiting NCT05439629 - Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration Phase 3
Recruiting NCT05197270 - 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration Phase 1/Phase 2
Terminated NCT05473715 - A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment Phase 4
Recruiting NCT06346600 - A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD